MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100606-PIP01-22) and to the deferral

MHRA-100606-PIP01-22-M01

Scope of the Application

Active Substance(s)

sparsentan

Condition(s)

Treatment of focal segmental glomerulosclerosis

Pharmaceutical Form(s)

Tablet, Oral suspension

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Vifor (International) Inc

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Vifor (International) Inc submitted to the licensing authority on 20/04/2023 13:23 BST an application for a Modification

The procedure started on 20/09/2023 09:32 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100606-PIP01-22-M01

Of 09/10/2023 13:54 BST

On the adopted decision for sparsentan (MHRA-100606-PIP01-22-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for sparsentan , Tablet, Oral suspension , ORAL USE .

This decision is addressed to Vifor (International) Inc, Rechenstrasse 37, St Gallen, SWITZERLAND, 9001

ANNEX I

1. Waiver

1.1 Condition:

Treatment of focal segmental glomerulosclerosis The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 1 year Pharmaceutical form(s): Tablet Oral suspension Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of focal segmental glomerulosclerosis

2.2 Indication(s) targeted by the PIP:

Treatment of focal segmental glomerulosclerosis

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 1 year to less than 18 years of age

2.4 Pharmaceutical Form(s):

Tablet Oral suspension

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Age-appropriate oral liquid dosage form and suitable medical administration device for dosing children 1 years of age and older.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	3	Study 2 (RET-D-001/DUET Extension) Open-label treatment extension phase of study RET-D-001 (DUET), following its 8-week double-blind active-controlled (irbesartan) treatment period, to assess the long-term safety and sustainability of effect of sparsentan for up to 488 weeks, in patients from 8 years to less than 18 years of age (and adults) with biopsy-proven focal segmental glomerulosclerosis (FSGS) or documentation of a genetic mutation in a podocyte protein associated with FSGS. Study 3 (021FSGS16010/DUPLEX) Randomised, double-blind, active-control, parallel group study, to assess the long-term efficacy and safety of sparsentan compared to irbesartan in patients from 8 years to less than 18 years of age (and adults) with biopsy-proven primary focal segmental glomerulosclerosis (FSGS) or documentation of a genetic mutation in a podocyte protein associated with FSGS. Study 4 (021-PED1) Open-label, uncontrolled, 2-part study to

		evaluate the pharmacokinetics and pharmacodynamics (part 1: 12-weeks), safety, and efficacy (part 2: 96-weeks) of once daily oral sparsentan (oral liquid suspension formulation) in children from 1 year to less than 18 years of age with focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).
Extrapolation, Modeling & Simulation Studies	2	Study 5 Physiologically based PK (PBPK) model to assess the impact of the physiochemical properties of a new paediatric oral suspension formulation under conditions of use, to support dose selection for paediatric patients from 1 year of age. Study 6 Population pharmacokinetic (PopPK) modelling and simulation study to evaluate the dose-exposure relationship in adults and in each paediatric subpopulation and disease population from 1 year to less than 18 years of age.
Other Studies	1	Study 7 (021FSGS16010/DUPLEX [interim analysis]) Interim analysis of study 021FSGS16010 (DUPLEX) to assess the long-term efficacy and safety of sparsentan compared to irbesartan in patients from 8 to less than 18 years of age (and adults) with focal segmental glomerulosclerosis (FSGS).
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	30/06/2026
Deferral of one or more studies contained in the paediatric investigation plan:	Yes